CORBF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CORBF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Global Cord Blood's average Accounts Receivable for the three months ended in Mar. 2022 was $24.8 Mil. Global Cord Blood's Revenue for the three months ended in Mar. 2022 was $46.8 Mil. Hence, Global Cord Blood's Days Sales Outstanding for the three months ended in Mar. 2022 was 48.32.
The historical rank and industry rank for Global Cord Blood's Days Sales Outstanding or its related term are showing as below:
Global Cord Blood's Days Sales Outstanding increased from Mar. 2021 (39.04) to Mar. 2022 (48.32).
The historical data trend for Global Cord Blood's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Cord Blood Annual Data | |||||||||||||||||||||
Trend | Mar13 | Mar14 | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 41.09 | 39.11 | 30.72 | 35.72 | 42.32 |
Global Cord Blood Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 39.04 | 38.22 | 40.83 | 42.69 | 48.32 |
For the Diagnostics & Research subindustry, Global Cord Blood's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Global Cord Blood's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Global Cord Blood's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Global Cord Blood's Days Sales Outstanding for the fiscal year that ended in Mar. 2022 is calculated as
Days Sales Outstanding (A: Mar. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Mar. 2021 ) | + | Accounts Receivable (A: Mar. 2022 )) | / | count ) | / | Revenue (A: Mar. 2022 ) | * | Days in Period |
= | ( (20.012 | + | 25.424) | / | 2 ) | / | 195.955 | * | 365 |
= | 22.718 | / | 195.955 | * | 365 | ||||
= | 42.32 |
Global Cord Blood's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:
Days Sales Outstanding (Q: Mar. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2021 ) | + | Accounts Receivable (A: Mar. 2022 )) | / | count ) | / | Revenue (A: Mar. 2022 ) | * | Days in Period |
= | ( (24.19 | + | 25.424) | / | 2 ) | / | 46.844 | * | 365 / 4 |
= | 24.807 | / | 46.844 | * | 365 / 4 | ||||
= | 48.32 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Cord Blood (OTCPK:CORBF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Global Cord Blood's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Kent C Mccarthy | 10 percent owner, other: Mbr 13(d) grp own 10% plus | 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451 |
Jayhawk Private Equity Fund Ii Lp | 10 percent owner | 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205 |
7-2010 Grat 5 Under Kent C. Mccarthy Grat Tr Dtd 4-23-2010 | other: 13 (d) group owning > 10% | 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216 |
7-2010 Grat 6 Under Kent C Mccarthy Grat Tr Dtd 4-23-2010 | 10 percent owner, other: Member of 13(d) group owning m | 7335 COTTONWOOD, SHAWNEE KS 66216 |
Mccarthy Family Sd, Llc | 10 percent owner, other: 13 (d) group owning > 10% | 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216 |
Jhab Fund Ii, Llc | other: 13(d) group owning > 10% | 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216 |
Jhab Management Ii, Llc | other: 13(d) group owning > 10% | 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216 |
Jcf Co Lf, L.p. | other: 13(d) group owning > 10% | 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451 |
Jayhawk Capital Management Llc | other: Member of the group | 13021 W 74TH ST, SHAWNEE KS 66216 |
Jayhawk China Fund Cayman Ltd | other: Member of the group | 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451 |
Jayhawk Private Equity Gp Ii, L.p. | 10 percent owner | 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205 |
Jayhawk Private Equity, Llc | 10 percent owner | 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205 |
From GuruFocus
By PRNewswire PRNewswire • 06-26-2022
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire PRNewswire • 07-09-2022
By PRNewswire PRNewswire • 04-29-2022
By Business Wire Business Wire • 05-27-2022
By PRNewswire PRNewswire • 07-06-2022
By Business Wire Business Wire • 06-03-2022
By PRNewswire PRNewswire • 05-20-2022
By PRNewswire PRNewswire • 12-07-2021
By Business Wire Business Wire • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.